Volume 34, Issue 3 (11-2010)                   Research in Medicine 2010, 34(3): 191-195 | Back to browse issues page

XML Persian Abstract Print


Department of Medical Oncology and Hematology, Taleghani Teaching Hospital, Shahid Beheshti University, M.C., Tehran, Iran , ghadianymojtaba@yahoo.com
Abstract:   (14159 Views)
Abstract Background: Breast cancer is more common in women with high serum testosterone level. Few studies showed that high level of serum testosterone is associated with poor prognosis. The association of testosterone level with histopathological findings has not been studied yet. In this study we investigated this association. Methods: Patients referred to a medical oncology clinic with no history of previous chemotherapy, hormone therapy, oophorectomy, or other cancers enrolled in the study. Morning serum testosterone was checked. Histopathologic findings were extracted from pathologic reports. Relationship between testosterone level and histopathologic types was analysed. Results: 106 patients were studied whose mean age was 47±10 years. 63.2% of our patients were premenopausal. Histopathologic factors were unfavourable in 50%. The rate of vascular invasion was 56.4% and 73% were receptor positive. Mean level of serum testosterone was 0.56±0.52 ng/ml in patients with favourable histopathology and 0.70 ±0.77 ng/ml with unfavourable histopathology (p<0.4). No testosterone level was above normal range. Conclusion: There was no relation between serum testosterone level and histopathologic findings viz. serum testosterone level was not higher in breast cancers with unfavourable histopathologic factors. So we need to conduct more studies to figure out the reasons for the poor prognosis observed in patients with higher levels of serum testosterone. Keywords: Breast cancer, Testosterone, Prognosis.
Full-Text [PDF 174 kb]   (8014 Downloads)    
Type of Study: Original |
Received: 2011/02/13 | Published: 2010/11/15

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.